Komori
Business Alliances4892Cyfuse Biomedical K.K.Pharmaceuticals

Notice regarding the commencement of a physician-initiated clinical trial based on joint research with Keio University and Fujita Health University

A physician-initiated clinical trial to evaluate the safety and efficacy of the clinical trial product "KCF-BC1," developed through joint research by Keio University, Fujita Health University and Cyfuse, will commence at Keio University Hospital.

Worth reading
40Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Business Alliances
4892Cyfuse Biomedical K.K.
Alliance partnerDepartment of Orthopaedic Surgery, School of Medicine, Keio University / Fujita Health University
About the partner
Business DescriptionDepartment of Orthopaedic Surgery, School of Medicine / A university with the Tokyo Advanced Medical Research Center
LocationTokyo Metropolitan Government
Impact on Business Performance

Impact on results for the fiscal year ending December 2026: currently under review

Agreements reached under this partnership
ItemDetails
Name of alliance partnerDepartment of Orthopaedic Surgery, School of Medicine, Keio University, Fujita Health University
Alliance partner's business activitiesDepartment of Orthopaedic Surgery, School of Medicine, A university with the Tokyo Advanced Medical Research Center
Alliance partner's locationTokyo Metropolitan Government
Type of allianceBusiness Alliances
Impact on Business PerformanceImpact on results for the fiscal year ending December 2026: currently under review
Items this document does not state (18)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeDetails of the allianceNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To evaluate the safety and efficacy of the clinical trial product "KCF-BC1" developed through the joint research.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice regarding the commencement of a physician-initiated clinical trial based on joint research with Keio University and Fujita Health University | Cyfuse Biomedical K.K. (4892) timely disclosure | Komori